SALT LAKE CITY--(BUSINESS WIRE)--Foldax®, Inc. today announced the appointment of medical device veteran Scott Huennekens as an independent member of the company’s board of directors. Huennekens possesses more than 30 years of experience in the medical device industry, leading high-profile companies through IPOs and acquisitions, and serving on the board of directors for several innovative startups.
He previously served as President and CEO of Verb Surgical, the robotics venture created by Google and J&J to revolutionize the future of surgery, which was subsequently wholly acquired by J&J. Prior to that, he led Volcano Corp., an innovator in catheter-based imaging for the heart, as its first and only President and CEO from start-up to IPO to its sale to Philips. Earlier, as President and CEO of Digirad Corporation, a diagnostic imaging solutions provider, he led the company through an IPO. He currently serves on the board of directors for Nuvasive, Acutus Medical, KARDION GmbH, Proximie, Q’Apel Medical, Hyperfine, Envista Holdings and Wondr Medical.
“We are delighted to welcome Scott to our board. He brings invaluable experience in several areas important for Foldax, including cardiovascular technology, robotics and business strategy. Importantly, Scott has been involved in several innovative ventures, such as Verb Surgical, which have had visionary missions to change the status quo – this is exactly what Foldax intends to do by transforming the heart valve space with its novel biopolymer valve,” said Foldax CEO Frank Maguire.
“I am pleased to be joining the Foldax board. I believe Foldax is positioned to make the next significant advancement in heart valves since transcatheter valve replacement. My experience in leading innovative technologies on both the management and board sides can add value to Foldax’s commercialization efforts. I look forward to working with the board and management team to ensure the realization of Foldax’s potential,” said Scott Huennekens.
Headquartered in Salt Lake City, Utah, Foldax is reinventing every aspect of the heart valve – from material to design to manufacturing – to develop surgical and transcatheter valves designed to last a lifetime addressing historical tradeoffs.
Foldax investors include Angel Physicians Fund, Biostar Capital, Caltech, Kairos Ventures, Memorial Care Innovation Fund and Sayan Bioventures.
The Tria heart valve is considered investigational in the U.S. and is not available for commercial sale in the U.S.